Wire · opportunities
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
Arbutus and licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech over lipid nanoparticle (LNP) technology used in COVID-19 vaccines, seeking injunctions and damages across Canada and 20 European countries. The company also received $178M from a Moderna settlement and plans to return approximately $230M to shareholders.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you licence biotech IP to vaccine or therapeutics makers, Arbutus just proved the royalty model works at scale: $178M from Moderna, and now leverage to extract damages from Pfizer and BioNTech across two continents. Your patent portfolio is now an asset class, not a defensive moat.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics